Credit Suisse Maintains Outperform on NuVasive, Raises Price Target to $87

Credit Suisse analyst Matt Miksic maintains NuVasive (NASDAQ:NUVA) with a Outperform and raises the price target from $76 to $87.

Benzinga · 01/08/2020 15:50

Credit Suisse analyst Matt Miksic maintains NuVasive (NASDAQ:NUVA) with a Outperform and raises the price target from $76 to $87.